Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Jackson

Physician Assistant Virginia Beach, VA Physician Assistant

NPI 1982623625 CMS profile 10465982

5249 Providence Rd, Virginia Beach, VA 23464

Open in the dashboard

General payments

$11,587

617 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Jackson of Virginia Beach, VA is reported in the CMS Open Payments database as having received $11,587 across 617 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,328 142
2024 General $2,643 132
2023 General $2,133 91
2022 General $2,294 124
2021 General $2,190 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Jackson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Timothy Jackson were reported at $2,328. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Timothy Jackson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,190 $132 $37–$438 $132
2022 $2,294 $155 $48–$522 $149
2023 $2,133 $167 $52–$557 $160
2024 $2,643 $178 $55–$600 $164
2025 $2,328 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,499 192 payments
  2. Janssen Biotech, Inc. $1,216 67 payments
  3. Genzyme Corporation $939 38 payments
  4. LEO Pharma Inc. $762 60 payments
  5. Regeneron Healthcare Solutions, Inc. $638 29 payments
  6. Arcutis Biotherapeutics, Inc. $604 21 payments
  7. Amgen Inc. $542 21 payments
  8. E.R. Squibb & Sons, L.L.C. $500 31 payments
  9. Pfizer Inc. $446 35 payments
  10. Sun Pharmaceutical Industries Inc. $443 22 payments
  11. Other $1,998 101 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,036 609 payments
  2. Education $551 8 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,636 87 payments
  2. SKYRIZI $1,578 84 payments
  3. DUPIXENT Immunology $1,305 51 payments
  4. TREMFYA $1,194 56 payments
  5. HUMIRA $828 51 payments
  6. DUPIXENT Inflammation And Immunology $561 25 payments
  7. Otezla $542 21 payments
  8. SOTYKTU $500 31 payments
  9. ADBRY $494 34 payments
  10. TALTZ $400 24 payments
  11. Other $4,870 320 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,048

Median for Physician Assistant: 241

Drug cost

$325,654

Median for Physician Assistant: $4,110

Branded share of claims

16%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 23 $134,812
Dupixent Pen Dupilumab Brand 21 $86,036
Taltz Autoinjector Ixekizumab Brand 11 $76,698
Clobetasol Propionate Generic 53 $3,234
Fluocinonide Generic 69 $2,690
Fluorouracil Generic 27 $2,264
Triamcinolone Acetonide Generic 117 $1,937
Tretinoin Generic 27 $1,907
Metronidazole Generic 34 $1,832
Ketoconazole Generic 101 $1,549

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$458,089

Of which drugs: $486

Medicare patients

1,505

Average age 75

Services billed

12,396

664 women, 841 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 43%
Diabetes 23%
Ischemic heart disease 21%
Atrial fibrillation 18%
Cancer 16%
Chronic kidney disease 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 46 78 $414
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 74 97 $72

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$535 — —
SKYRIZI
$429 — —
TREMFYA
$363 — —
DUPIXENT
$325 21 —
Zoryve
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record